The route of Leishmania tropica infection determines disease outcome and protection against Leishmania major in BALB/c mice

Korean Journal of Parasitology

Volumn 51, Issue 1, 2013, Pages 69-74

  Mahmoudzadeh Niknam, Hamid ^a   Khalili, Ghader ^a   Abrishami, Firoozeh ^a   Najafy, Ali ^a   Khaze, Vahid ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Disease outcome; Immunity; Intradermal; Leishmania major; Leishmania tropica; Subcutaneous

Indexed keywords

INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DELAYED HYPERSENSITIVITY; EXPERIMENTAL INFECTION; FEMALE; GENETIC STRAIN; IMMUNOSTIMULATION; INFECTION PREVENTION; INNATE IMMUNITY; INTRACUTANEOUS TEST; LEISHMANIA MAJOR; LEISHMANIA TROPICA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE LOAD; PROMASTIGOTE; PROVOCATION TEST; SKIN LEISHMANIASIS; WOUND HEALING IMPAIRMENT;

DISEASE OUTCOME; IMMUNITY; INTRADERMAL; LEISHMANIA MAJOR; LEISHMANIA TROPICA; SUBCUTANEOUS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS; MICE; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 84874619647     PISSN: 00234001     EISSN: 17380006     Source Type: Journal    
DOI: 10.3347/kjp.2013.51.1.69     Document Type: Article

References (22)

1. World Health Organization. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, WHO Technical Report Series, No. 949. Geneva, Switzerland. 2010.
2. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Viscerotropic growth pattern of Leishmania tropica in BALB/c mice is suggestive of a murine model for human viscerotropic leishmaniasis. Korean J Parasitol 2007; 45: 247-253.
3. Lira R, Méndez S, Carrera L, Jaffe C, Neva F, Sacks D. Leishmania tropica: the identifcation and purifcation of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease. Exp Parasitol 1998; 89: 331-342.
4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858.
5. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice. Korean J Parasitol 2007; 45: 103-109.
6. Constant SL, Lee KS, Bottomly K. Site of antigen delivery can infuence T-cell priming: pulmonary environment promotes preferential Th2-type differentiation. Eur J Immunol 2000; 30: 840-847.
7. Méndez S, Belkaid Y, Seder RA, Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002; 20: 3702-3708.
8. Bhowmick S, Mazumdar T, Ali N. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun 2009; 77: 1514-1523.
9. Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, Belkaid Y, Sacks DL. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005; 73: 4714-4722.
10. Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, Rowton E, Ribeiro J, Sacks DL. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-1953.
11. Kaur S, Kaur T, Garg N, Mukherjee S, Raina P, Athokpam V. Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 2008; 103: 1413-1419.
12. Mahmoudzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M, Alimohammadian MH, Parvizi P, Hatam GR, Mohebali M, Khalaj V. The problem of mixing up of Leishmania isolates in the laboratory: suggestion of ITS1 gene sequencing for verifcation of species. Iran J Parasitol 2011; 6: 41-48.
13. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice. Exp Parasitol 2011; 127: 448-453.
14. Mahmoudzadeh-Niknam H. Induction of partial protection against Leishmania major in BALB/c mice by Leishmania tropica. Scand J Lab Anim Sci 2004; 31: 201-207.
15. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010; 147: 342-349.
16. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 2009; 32: 118-128.
17. Sacks DL, Melby PC. Animal models for the analysis of immune responses to leishmaniasis. In Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W eds, Current Protocols in Immunology, Vol 4. New York, USA. John Wiley & Sons. 1998, p 1921-1922.
18. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin 2011; 7: 811-827.
19. Kautz-Neu K, Noordegraaf M, Dinges S, Bennett CL, John D, Clausen BE, von Stebut E. Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 2011; 208: 885-891.
20. Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005; 169: 569-576.
21. Kirkpatrick CE, Nolan TJ, Farrell JP. Rate of Leishmania-induced skin-lesion development in rodents depends on the site of inoculation. Parasitology 1987; 94: 451-465.
22. Baldwin TM, Elso C, Curtis J, Buckingham L, Handman E. The Site of Leishmania major infection determines disease severity and immune responses. Infect Immun 2003; 71: 6830-6834.